
Christelle Bouchart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8001533/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. Tumor Biology, 2015, 36, 1943-1953.	0.8	37
2	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093609.	1.4	21
3	Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2. Cancer Medicine, 2020, 9, 1069-1078.	1.3	18
4	Discovery and 3D imaging of a novel ΔNp63-expressing basal cell type in human pancreatic ducts with implications in disease. Gut, 2022, 71, 2030-2042.	6.1	15
5	What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?. Annals of Surgical Oncology, 2021, 28, 6211-6222.	0.7	15
6	Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind. Cancers, 2021, 13, 1231.	1.7	14
7	EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Endoscopy International Open, 2021, 09, E253-E257.	0.9	9
8	lsotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110458.	1.4	9
9	Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045860.	1.4	Ο